Showing results (221-230 of 247) with videos related to
Sort By:
Pageof 25
Current Medical Research and Opinion|August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapyMario Campone, J Thaddeus Beck, Michael Gnant, et al.The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.Gynecologic Oncology|October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerElizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialIngo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyCharles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I Gordon, Jason B Kaplan, Rakesh Popat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2Gabriel N Hortobagyi, David Chen, Martine Piccart, et al.Pageof 25